What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
His primary areas of study are Cancer, Immunology, Cancer research, Head and neck squamous-cell carcinoma and Internal medicine.
His work deals with themes such as Surgery and Pathology, which intersect with Cancer.
The Cancer research study combines topics in areas such as Cell culture, Protein kinase B, Epidermal growth factor receptor, Cancer cell and Gene.
His Head and neck squamous-cell carcinoma study incorporates themes from Receptor and Downregulation and upregulation.
His research on Internal medicine frequently connects to adjacent areas such as Oncology.
He has included themes like Head and neck, Carcinoma, Chemotherapy and Hazard ratio in his Oncology study.
His most cited work include:
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck (1979 citations)
- Comprehensive genomic characterization of head and neck squamous cell carcinomas (1933 citations)
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma (1325 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Oncology, Head and neck cancer, Cancer research and Cancer are his primary areas of study.
In the field of Internal medicine, his study on Cetuximab and Nivolumab overlaps with subjects such as In patient.
His Oncology study combines topics from a wide range of disciplines, such as Chemotherapy, Cisplatin, Clinical endpoint, Carcinoma and Stage.
His studies deal with areas such as Clinical trial, Disease and Nuclear medicine as well as Head and neck cancer.
The concepts of his Cancer research study are interwoven with issues in Head and neck squamous-cell carcinoma, CD8, Immunology and Immunotherapy.
His Cancer research is multidisciplinary, incorporating elements of Surgery and Pathology.
He most often published in these fields:
- Internal medicine (31.05%)
- Oncology (26.30%)
- Head and neck cancer (23.92%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (31.05%)
- Cancer research (22.88%)
- Head and neck squamous-cell carcinoma (19.17%)
In recent papers he was focusing on the following fields of study:
Robert L. Ferris mostly deals with Internal medicine, Cancer research, Head and neck squamous-cell carcinoma, Oncology and Head and neck cancer.
His Clinical trial, Hazard ratio and Cohort study study, which is part of a larger body of work in Internal medicine, is frequently linked to In patient, bridging the gap between disciplines.
The various areas that Robert L. Ferris examines in his Cancer research study include T cell, CD8, Immune system and Immunotherapy.
His Head and neck squamous-cell carcinoma study which covers Cetuximab that intersects with Methotrexate.
His Oncology research includes elements of Pembrolizumab, Chemotherapy, Phases of clinical research, Head and neck and Nivolumab.
His study focuses on the intersection of Head and neck cancer and fields such as Stereotactic body radiation therapy with connections in the field of Re-Irradiation and Toxicity.
Between 2018 and 2021, his most popular works were:
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) (115 citations)
- Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study. (105 citations)
- The changing therapeutic landscape of head and neck cancer. (94 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
His scientific interests lie mostly in Internal medicine, Oncology, Head and neck cancer, Immunotherapy and Head and neck squamous-cell carcinoma.
He studied Internal medicine and Gastroenterology that intersect with Taxane, Cytology, Predictive value of tests and Thyroid nodules.
His Oncology research includes themes of Clinical trial, Chemotherapy, Phases of clinical research, Stage and Nivolumab.
His Head and neck cancer research is included under the broader classification of Cancer.
His work carried out in the field of Immunotherapy brings together such families of science as Blockade and Cancer research.
His Head and neck squamous-cell carcinoma research is multidisciplinary, relying on both Tremelimumab and Durvalumab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
